dr. HM (Hedwig) Blommestein

Erasmus School of Health Policy & Management

Associate professor | Health Technology Assessment (HTA)

Email: blommestein@eshpm.eur.nl

Pure profile

Work

Noor Wortelboer, Seamus Kent, Inge R. Konings, Annemiek van Ommen-Nijhof, Vincent van der Noort, Esther van den Pol, Cristina Guerrero Páez, Marlies L. van Bekkum, Franchette W.P.J. van den Berkmortel, Helga J. Droogendijk, Danny Houtsma, Hendrika M. Oosterkamp, Annemieke van der Padt-Pruijsten, Ester J.M. Siemerink, Jolien Tol, Annette A. van Zweeden, A. Elise van Leeuwen-Stok, Gabe S. Sonke, Agnes Jager & Hedwig Blommestein (2025) - Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial - European Journal of Cancer, 231 - doi: 10.1016/j.ejca.2025.116051 - [link]
Diego A. Larrotta-Castillo, Hedwig M. Blommestein, Britt Kunnen, Joan J. Penninkhof, Agustinus J.A.J. van de Schoot, Mischa S. Hoogeman & Steven F. Petit (2025) - Cost-benefit analysis of advanced CBCT imaging: Incremental costs and savings - Radiotherapy and Oncology, 211 - doi: 10.1016/j.radonc.2025.111106 - [link]
Yi Hsuan Chen, Michiel Kroesen, Mischa S. Hoogeman, Matthijs M. Versteegh, Carin A. Uyl-de Groot & Hedwig M. Blommestein (2025) - Reply to comment on Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study - Clinical and Translational Radiation Oncology, 54 - doi: 10.1016/j.ctro.2025.101013 - [link]
Saskia de Groot, Hedwig M. Blommestein, Brenda Leeneman, Carin A. Uyl-de Groot, John B.A.G. Haanen, Michel W.J.M. Wouters, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Willeke A.M. Blokx, Marye J. Boers-Sonderen, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Olivier J. van Not, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk & Pieter H.M. van Baal (2025) - Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma - Medical Decision Making, 45 (3), 302-317 - doi: 10.1177/0272989X251319338 - [link]
Hedwig M. Blommestein, Saskia de Groot, Brenda Leeneman, Carin A. Uyl-de Groot, John B.A.G. Haanen, Michel W.J.M. Wouters, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Willeke A.M. Blokx, Marye J. Boers-Sonderen, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Olivier J. van Not, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk & Margreet G. Franken (2025) - Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model - European Journal of Cancer, 218 - doi: 10.1016/j.ejca.2024.115071 - [link]
Yi Hsuan Chen, Michiel Kroesen, Mischa Hoogeman, Matthijs Versteegh, Carin Uyl-de Groot & Hedwig M. Blommestein (2025) - Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study - Clinical and Translational Radiation Oncology, 51 - doi: 10.1016/j.ctro.2025.100913 - [link]
Gabe S. Sonke, Annemiek van Ommen-Nijhof, , Noor Wortelboer, Vincent van der Noort, Astrid C.P. Swinkels, Hedwig M. Blommestein, Cristina Guerrero Paez, Linda Mol, Aart Beeker, Karin Beelen, Lisanne C. Hamming, Joan B. Heijns, Aafke H. Honkoop, Paul C. de Jong, Quirine C. van Rossum-Schornagel, Christa van Schaik-van de Mheen, Jolien Tol, Cathrien S. Tromp-van Driel, Suzan Vrijaldenhoven, A. Elise van Leeuwen-Stok, Inge R. Konings & Agnes Jager (2024) - Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature, 636 (8042), 474-480 - doi: 10.1038/s41586-024-08035-2 - [link]
Christine Bennink, Mirian Brink, Saskia F.A. Duijts, Hans Scheurer, Pieter Sonneveld & Hedwig M. Blommestein (2024) - Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands - Clinical Lymphoma, Myeloma and Leukemia, 24 (9), 604-610 - doi: 10.1016/j.clml.2024.04.004 - [link]
M. R. Seefat, C. A.M. Stege, B. I. Lissenberg-Witte, M. D. Levin, G. J. Timmers, M. Hoogendoorn, P. F. Ypma, S. K. Klein, G. A. Velders, M. Westerman, L. Strobbe, N. Durdu-Rayman, M. A. Davidis-van Schoonhoven, R. J.W. van Kampen, A. C. Dijk, A. Koster, M. H. Silbermann, E. van der Spek, A. Beeker, Z. Erjavec, N. C.H.P. de Graauw, M. B.L. Leys, P. Sonneveld, N. W.C.J. van de Donk, K. Nasserinejad, H. M. Blommestein, D. G.J. Cucchi & S. Zweegman (2024) - Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial - European Journal of Cancer, 207 - doi: 10.1016/j.ejca.2024.114153 - [link]
M. R. Seefat, D. G.J. Cucchi, K. Groen, M. L. Donker, K. G. van der Hem, M. Westerman, A. M. Gerrits, A. Beeker, N. W.C.J. van de Donk, H. M. Blommestein & S. Zweegman (2024) - Treatment sequences and drug costs from diagnosis to death in multiple myeloma - European Journal of Haematology, 112 (3), 360-366 - doi: 10.1111/ejh.14119 - [link]
H. R. Mortensen, P. Populaire, L. Hoffmann, D. S. Moeller, A. Appelt, P. Nafteux, C. T. Muijs, C. Grau, M. A. Hawkins, E. G.C. Troost, G. Defraene, R. Canters, C. S. Clarke, D. C. Weber, E. W. Korevaar, K. Haustermans, M. Nordsmark, Val Gebski, M. P. Achiam, Sheraz R. Markar, Ganesh Radhakrishna, Maaike Berbee, Daniele Scartoni, Ester Orlandi, Jerome Doyen, Vincent Gregoire, Gilles Crehange, Johannes Langendijk, Paula Lorgelly, Hedwig M. Blommestein, Camilla S. Byskov, Mai L. Ehmsen, Maria Fuglsang Jensen, Gloria Vilches Freixas, Rebecca Bütoft & (2024) - Proton versus photon therapy for esophageal cancer – A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer - Radiotherapy and Oncology, 190 - doi: 10.1016/j.radonc.2023.109980 - [link]
Marianne Luyendijk, Agnes Jager, Sanne M. Buijs, Sabine Siesling, Carin A.Uyl de Groot & Hedwig M. Blommestein (2023) - Cost-Effectiveness Analysis of MammaPrint<sup>®</sup> to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer - PharmacoEconomics, 41 (8), 981-997 - doi: 10.1007/s40273-023-01277-4 - [link]
Brenda Leeneman, Hedwig M. Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E. Fibbe, Liesbeth Oosten, Carin A. Uyl-de Groot & Frederick W. Thielen (2023) - Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease - European Journal of Haematology, 111 (2), 240-246 - doi: 10.1111/ejh.13987 - [link]
Christine Bennink, Hans Westgeest, Daan Schoonen, Femke Boersen, Pieter Sonneveld, Jan Hazelzet, Hedwig Blommestein & Marjolein Van Der Klift (2023) - High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study - HemaSphere, 7 (6) - doi: 10.1097/HS9.0000000000000913 - [link]
Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H.J.T. de Hingh, Frank J.P. Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G.E. de Vries, Carin A. Uyl-de Groot & Sabine Siesling (2023) - Changes in survival in de novo metastatic cancer in an era of new medicines - Journal of the National Cancer Institute, 115 (6), 628-635 - doi: 10.1093/jnci/djad020 - [link]
Lj Bakker, Fw Thielen, WK Redekop, CA Uyl de Groot & Hm Blommestein (2023) - Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma - BMC Medical Research Methodology, 23 (1) - doi: 10.1186/s12874-023-01952-2 - [link]
Marianne Luyendijk, Hedwig Blommestein, Carin Uyl-de Groot, Sabine Siesling & Agnes Jager (2023) - Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands - JAMA network open, 6 (2) - doi: 10.1001/jamanetworkopen.2022.56170 - [link]
Elisabeth M. Jongbloed, Hedwig M. Blommestein, Hannah M. van Schoubroeck, John W.M. Martens, Saskia M. Wilting, Carin Uyl-de Groot & Agnes Jager (2023) - Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs? - Breast Cancer: Targets and Therapy, 15, 147-161 - doi: 10.2147/BCTT.S387375 - [link]
Yi Hsuan Chen, Hedwig M. Blommestein, Reinder Klazenga, Carin Uyl-de Groot & Marco van Vulpen (2023) - Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands - Cancers, 15 (2) - doi: 10.3390/cancers15020516 - [link]